Pramipexole to Enhance Social Connections
Key facts
- Who runs it
- University of California, San Diego
- Where
- New York and San Diego, United StatesSee the 2 sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 2
- People taking part
- 108 people, planned
- Started
- 13 May 2024
- Expected to end
- Mar 2027
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Pramipexole Pill
- Placebo Pill
- Record updated
- 13 October 2026
Who can take part
- Age
- 18 years to 50 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 27 criteriaShow less
Who can take part
- Clinically elevated levels of anxiety (OASIS ≥ 8) or depression or (PHQ-9 ≥ 10)
- Moderate or greater social disability assessed with clinician-rating (SDS - Social ≥ 5)
- Below the normative mean for temperamental reward sensitivity (ATQ - Approach < 35)
- Age 18-50
- Ability to provide written informed consent
- English proficiency
Who cannot take part
- Positive urinalysis screen for psychoactive drug use (that is not physician prescribed or THC)
- Women who are pregnant, breastfeeding, or planning to become pregnant within the next 6 months. Individuals of childbearing potential must agree to use an acceptable method of contraception from at least 21 days prior to the first dose of study drug and for 3 months after the last dose of study drug for study entry
- Concurrent empirically supported psychosocial treatments for anxiety or mood disorders (e.g., cognitive behavioral therapy)
- Use of any psychotropic medication (e.g. SSRIs, benzodiazepines) within 14 days before study entry [except for fluoxetine within 30 days]. Concurrent use is prohibited during the study
- History of bipolar or psychotic disorders
- History of major neurological disorder or moderate to severe traumatic brain injury
- History of severe or unstable medical conditions that might be compromised by participation in the study (e.g., cardiovascular, hepatic, renal, respiratory, endocrine, neurologic or hematologic disease; history of seizure disorder)
- Past 6-month substance use disorder (any severity) with the exception of mild alcohol, cannabis, or tobacco use disorder, which will be permitted in the study
- History of impulse control problems (e.g., pathological gambling)
- First-degree relative with a diagnosis of schizophrenia-spectrum or other psychotic disorder or bipolar disorder
- History of cocaine or stimulant use (e.g., amphetamine, cocaine, methamphetamine; except for physician prescribed stimulants) in the past 6 months
- History of dopaminergic agonists drug use (e.g., pramipexole, ropinirole, apomorphine, rotigotine) in the past 6 months
- Clinical conditions assessed by the interviewer that necessitate more imminent clinical care. These criteria are in place so participants with these other, more severe symptoms can be referred for appropriate services (e.g. self-injurious behavior or exposure to a severe traumatic event in the past week)
- Abnormal and clinically relevant blood count, liver, renal or EKG findings as determined by physician
- Current, imminent risk of suicide assessed with Clinical Interview and Columbia Suicide Severity Rating Scale (C-SSRS) "yes" response to items 4, 5 (past month), 6 (past 3 months), or suicide attempt in the past year
- Anticipated inability to attend regular study appointments
- Anticipated inability to complete the study procedures as determined by study personnel
- Non-correctable vision or hearing problems, as some tests require intact sensory functioning
- No telephone or easy access to telephone
- MRI contraindications
- CGI-S score of 6 or 7
Where in United States
- New York State Psychiatric InstituteNew York, United States
- University of California San DiegoSan Diego, United States
About the trial
What the trial wants to find out
This study seeks to understand if the medication pramipexole improves social connectedness and functioning in adults (ages 18-50) who experience anxiety or depression. The study plans to enroll 108 participants total across two sites (University of California San Diego and New York State Psychiatric Institute). Pramipexole will be given in a 6-week randomized, double-blind, placebo-controlled trial. Social reward processing will be assessed using measures of brain function (fMRI), behavior, and self-report at baseline and week 6. Knowledge gained from this study will help determine the therapeutic potential of targeting the dopamine system to remediate social disconnection as an anxiety and depression intervention.
The 3 groups in the trial
- Pramipexole 1 mg/dExisting treatment, for comparison
Each participant will take pramipexole in identical capsular form twice daily for 6 weeks.
Treatment: Pramipexole Pill
- Pramipexole 2.5 mg/dExisting treatment, for comparison
Each participant will take pramipexole in identical capsular form twice daily for 6 weeks.
Treatment: Pramipexole Pill
- PlaceboPlacebo, for comparison
Each participant will take placebo in identical capsular form twice daily for 6 weeks.
Treatment: Placebo Pill
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Targeting Dopamine-Mediated Social Reward Sensitivity to Remediate Social Disconnection
- Record updated
- 13 October 2026